IP Library Patent Application 17140257
Patent Application
App. No. 17/140,257

AFFINITY TAG NUCLEIC ACID AND PROTEIN COMPOSITIONS AND PROCESSES FOR USING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/140,257
Abstract

The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.

Claims (18)

1 . A composition comprising:

(i) a fusion antibody comprising an antibody portion and at least one affinity peptide portion at the amino terminus or the carboxyl terminus of said antibody portion, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group; and

(ii) a matrix comprising a metal or a second member of said affinity peptide group.

2 . The composition of claim 1 , wherein the at least one affinity peptide comprises one member of a peptide affinity group and the matrix comprises the second member of the affinity peptide group.

3 . The composition of claim 2 , wherein said peptide affinity group comprises: S-protein and S-peptide; Glutathione S-Transferase (GST) tag and Glutathione (GSH); Protein Kinase A catalytic subunit (PKA) recognition peptide and PKA; Hemagglutinin (HA) epitope tag peptide and HA; Ketosteroid Isomerase (KSI) tag and oligo Phe; Ketosteroid Isomerase (KSI) tag and oligo Leu; oligo Arg and oligo Glu; or oligo Arg and oligo Asp.

4 . The composition of claim 1 , wherein the affinity peptide comprises a metal binding peptide and the matrix comprises a metal.

5 . The composition of claim 4 , wherein said metal binding peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO:1), SPHHG (SEQ ID NO:2), SPHHGGSPHHG (SEQ ID NO:3), HPHHG (SEQ ID NO:4), HPHHGGHPHHG (SEQ ID NO:5), SPHHGGHPHHG (SEQ ID NO:6), HPHHGGSPHHG (SEQ ID NO:7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO:8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO:10), or HGLGHGHEQQHGLGHGH (SEQ ID NO:9).

6 . The composition of claim 1 , wherein the fusion antibody is bound to the matrix via the at least one affinity peptide portion.

7 . The composition of claim 2 , wherein the fusion antibody is bound to the matrix via the at least one affinity peptide portion.

8 . The composition of claim 3 , wherein the fusion antibody is bound to the matrix via the at least one affinity peptide portion.

9 . The composition of claim 4 , wherein the fusion antibody is bound to the matrix via the at least one affinity peptide portion.

10 . The composition of claim 5 , wherein the fusion antibody is bound to the matrix via the at least one affinity peptide portion.

11 . A fusion antibody comprising:

an antibody portion and at least one affinity peptide portion at the amino terminus or the carboxyl terminus of said antibody portion, wherein said affinity peptide comprises a metal binding peptide or is one member of a peptide affinity group.

12 . The fusion antibody of claim 11 , wherein the at least one affinity peptide comprises one member of a peptide affinity group.

13 . The fusion antibody of claim 12 , wherein said peptide affinity group comprises: S-protein and S-peptide; Glutathione S-Transferase (GST) tag and Glutathione (GSH); Protein Kinase A catalytic subunit (PKA) recognition peptide and PKA; Hemagglutinin (HA) epitope tag peptide and HA; Ketosteroid Isomerase (KSI) tag and oligo Phe; Ketosteroid Isomerase (KSI) tag and oligo Leu; oligo Arg and oligo Glu; or oligo Arg and oligo Asp.

14 . The fusion antibody of claim 11 , wherein the affinity peptide comprises a metal binding peptide.

15 . The fusion antibody of claim 14 , wherein said metal binding peptide comprises oligohistidine or an oligopeptide comprising the sequence HGGHHG (SEQ ID NO:1), SPHHG (SEQ ID NO:2), SPHHGGSPHHG (SEQ ID NO:3), HPHHG (SEQ ID NO:4), HPHHGGHPHHG (SEQ ID NO:5), SPHHGGHPHHG (SEQ ID NO:6), HPHHGGSPHHG (SEQ ID NO:7), KDHLIHNVHKEEHAHAHNK (SEQ ID NO:8), GHGLGHGHEQQHGLGHGHK (SEQ ID NO:10), or HGLGHGHEQQHGLGHGH (SEQ ID NO:9).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2021
From: RABBANI, ELAZAR; STAVRIANOPOULOS, JANNIS G.; CARCAMO, JUAN; PATTON, WAYNE; DONEGAN, JAMES J.
To: ENZO BIOCHEM, INC.
Reel/Frame 055107/0327 →